Skip to main content
| News

Artidis ends successful study

26.06.2020

Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.

The team of Artidis, a spin-off from the University of Basel (img: Artidis)

Artidis has developed an innovative nanomechanical biomarker for cancer diagnosis and therapeutic optimization using the company’s own platform. By merging various medical data, the platform aims to make diagnosis quicker and create personalized plans for cancer treatment. This platform and therefore also the biomarker have recently been investigated in the NANO study according to a press release from Artidis, with the primary endpoint of the study being met.

The endpoint was sensitivity, which is a percentage showing the number patients for whom a disease was actually recognized. The primary endpoint of the NANO study was 90 percent, and a value of 96 percent was achieved. As such, the study endpoint was met, meaning that the nanomechanical biomarkers can be used for breast cancer biopsy in a clinical setting. The data from 520 patients were gathered in the analysis.

Marija Plodinec, CEO of Artidis, is quoted in the article: “We are very pleased with the excellent results from this first prospective study conducted in Switzerland.” With this having proven the clinical benefit of the nanomechanical biomarker, she goes on to add: “We are convinced that this brings us one step closer to providing patients undergoing a biopsy procedure with a same day diagnosis.”

Artidis is a spin-off from a research group at the University of Basel and the Swiss Nanoscience Institute. Artidis has already taken part in the Venture Mentoring Program run by the investment and innovation promotion agency Basel Area Business & Innovation. The NANO study was conducted at the University Hospital Basel Breast Care Centre and the University of Basel Biozentrum.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ground-breaking oncology being developed in the Basel Area

The Basel Area – covering northwestern Switzerland – has seen tremendous growth in recent years, and has become a true...

Read More
Genedata expanding its user network
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Genedata expanding its user network

The Japanese biopharmaceutical firm Ajinomoto is to use the Genedata solution to accelerate its drug development processes at its site...

Read More
Basel Area Business & Innovation, Invest

How Moderna is growing in Switzerland

The number one rule in real estate is “Location, Location, Location.” The global biotech company Moderna found its location in...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sandoz decides on Basel for headquarters

Sandoz AG will continue to have its headquarters in Basel as an independent company. The separation from Novartis is expected...

Read More
VectivBio sold for approximately 1 billion dollars
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio sold for approximately 1 billion dollars

The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

University of Basel and RocketVax present new Covid vaccine

Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...

Read More
1 2 3 64

Do you have a question? We'd like to hear from you.